Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer

Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient’s response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Braydon, Clifton, Samuel, Locke, Warwick, Luu, Phuc-Loi, Du, Qian, Lam, Dilys, Armstrong, Nicola J., Kumar, Beena, Deng, Niantao, Harvey, Kate, Swarbrick, Alex, Ganju, Vinod, Clark, Susan J., Pidsley, Ruth, Stirzaker, Clare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684655/
https://www.ncbi.nlm.nih.gov/pubmed/34922619
http://dx.doi.org/10.1186/s13148-021-01210-6
_version_ 1784617662799675392
author Meyer, Braydon
Clifton, Samuel
Locke, Warwick
Luu, Phuc-Loi
Du, Qian
Lam, Dilys
Armstrong, Nicola J.
Kumar, Beena
Deng, Niantao
Harvey, Kate
Swarbrick, Alex
Ganju, Vinod
Clark, Susan J.
Pidsley, Ruth
Stirzaker, Clare
author_facet Meyer, Braydon
Clifton, Samuel
Locke, Warwick
Luu, Phuc-Loi
Du, Qian
Lam, Dilys
Armstrong, Nicola J.
Kumar, Beena
Deng, Niantao
Harvey, Kate
Swarbrick, Alex
Ganju, Vinod
Clark, Susan J.
Pidsley, Ruth
Stirzaker, Clare
author_sort Meyer, Braydon
collection PubMed
description Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient’s response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-021-01210-6.
format Online
Article
Text
id pubmed-8684655
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86846552021-12-20 Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer Meyer, Braydon Clifton, Samuel Locke, Warwick Luu, Phuc-Loi Du, Qian Lam, Dilys Armstrong, Nicola J. Kumar, Beena Deng, Niantao Harvey, Kate Swarbrick, Alex Ganju, Vinod Clark, Susan J. Pidsley, Ruth Stirzaker, Clare Clin Epigenetics Short Report Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient’s response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-021-01210-6. BioMed Central 2021-12-18 /pmc/articles/PMC8684655/ /pubmed/34922619 http://dx.doi.org/10.1186/s13148-021-01210-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Meyer, Braydon
Clifton, Samuel
Locke, Warwick
Luu, Phuc-Loi
Du, Qian
Lam, Dilys
Armstrong, Nicola J.
Kumar, Beena
Deng, Niantao
Harvey, Kate
Swarbrick, Alex
Ganju, Vinod
Clark, Susan J.
Pidsley, Ruth
Stirzaker, Clare
Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
title Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
title_full Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
title_fullStr Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
title_full_unstemmed Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
title_short Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
title_sort identification of dna methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684655/
https://www.ncbi.nlm.nih.gov/pubmed/34922619
http://dx.doi.org/10.1186/s13148-021-01210-6
work_keys_str_mv AT meyerbraydon identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT cliftonsamuel identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT lockewarwick identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT luuphucloi identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT duqian identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT lamdilys identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT armstrongnicolaj identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT kumarbeena identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT dengniantao identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT harveykate identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT swarbrickalex identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT ganjuvinod identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT clarksusanj identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT pidsleyruth identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer
AT stirzakerclare identificationofdnamethylationbiomarkerswithpotentialtopredictresponsetoneoadjuvantchemotherapyintriplenegativebreastcancer

Ejemplares similares